anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
This cross-sectional, controlled study aims to explore kinesiophobia levels in postmenopausal women with osteoporosis compared to healthy age-matched controls. Postmenopausal osteoporosis is a systemic condition characterized by reduced bone mineral density, which increases fracture risk and can significantly affect individuals' physical activity and overall quality of life. Kinesiophobia, or the irrational fear of movement due to perceived injury risk, can further exacerbate this issue by restricting physical activity, which is vital for maintaining bone health. The study will involve 60 postmenopausal women diagnosed with osteoporosis and 60 healthy age-matched women without osteoporosis or osteopenia. Participants will be recruited from the outpatient clinics of İstanbul Physical Therapy and Rehabilitation Training and Research Hospital between January 21, 2024, and February 21, 2024. The study will assess kinesiophobia using the Turkish version of the Tampa Scale for Kinesiophobia (TSK), quality of life with the Quality of Life Questionnaire of the European Foundation for Osteoporosis (QUALEFFO-41), and symptoms of depression and anxiety using the Hospital Anxiety and Depression Scale (HADS). Additionally, the Tinetti Falls Efficacy Scale (TFES) will evaluate fear of falling, and bone mineral density will be measured using dual-energy X-ray absorptiometry (DXA).
The trocserutin is used in medicine as a medicamentous form for reducing the increased permeability of the capillaries. It has expressed venotonic effect. By the method high yield and purity trocserutin is produced. The hydroxyethylation of the rutin occurs in aqueous medium at temperature range from 55 to 80 deg.C in the presence of ammonium hydroxide catalyst in quantity ranging from 0.1-0.5 mol/mol rutin, with 3 to 7 mol ethylene oxide/mol rutin until reaching pH 9.2-9.4. Then the solution is cooled, acidified, preferably by organic acid, is filtered and is passed through reverse osmosis module. 2 claims
The present invention concerns compositions comprising and methods of identification and use of targeting peptides selective for cancer tissue, particularly prostate or ovarian cancer tissue. The method may comprise identifying endogenous mimeotopes of such peptides, such as GRP78, IL-11Rα and hsp90. Antibodies against such targeting peptides or their mimeotopes may be used for detection, diagnosis and/or staging of prostate or ovarian cancer. In other embodiments, the compositions and methods concern  novel type of gene therapy vector, known as adeno-associated phage (AAP). AAP are of use for targeted delivery of therapeutic agents to particular tissues, organs or cell types, such as prostate or ovarian cancer. In still other embodiments, targeting peptides selective for low-grade lipomas may be used for detection, diagnosis and targeted delivery of therapeutic agents.
The invention discloses an externally-used liquid medicine for treating tenosynovitis of hand flexor tendons. The externally-used liquid medicine is prepared by soaking parts by weight of following Chinese herbs with yellow wine: 10-20 parts of crystobalite, 10-20 parts of magnetite, 5-15 parts of bidentate achyranthes, 5-15 parts of dendrobe, 5-10 parts of cinnamomum cassia, 5-10 parts of aleppo avens, 5-10 parts of radix rehmanniae, 5-10 parts of notopterygium incisum, 3-8 parts of radix saposhnikoviae, 3-8 parts of safflower, 3-8 parts of radix angelicae sinensis, 3-8 parts of unprocessed licorice, 1-5 parts of eucommia ulmoides, 1-5 parts of antelope horn, 1-5 parts of astragalus membranaceus, 1-5 parts of peach kernel, 1-5 parts of white poria, 1-5 parts of fructus aurantii, 1-5 parts of wild jujube seeds, 1-5 parts of caulis spatholobi, 1-5 parts of astragalus henryl and 1-5 parts of ganoderma lucidum. The externally-used liquid medicine is short in course of treatment, quick in effect, good in treatment effect, low in treatment cost and free of obvious side effects and adverse reactions, and the tenosynovitis of hand flexor tendons is unlikely to recur. The invention further discloses a preparation method of the externally-used liquid medicine for treating the tenosynovitis of hand flexor tendons. The preparation method comprises the following main steps: (1) primarily soaking; (2) secondarily soaking; (3) combining leachates. The preparation method is simple in steps and good in leaching effect.
PCT No. PCT/JP95/00968 Sec. 371 Date Mar. 14, 1997 Sec. 102(e) Date Mar. 14, 1997 PCT Filed May 19, 1995 PCT Pub. No. WO95/32219 PCT Pub. Date Nov. 30, 1995The present invention provides a protein or polypeptide substance having at least one amino group bonded to a polyethyleneglycolosy group represented by the following general formula; R1-(OCH2 CH2)n-O-(wherein R1 represents an optionally substituted cholesteryl group; and n represents a positive integer which is arbitrarily variable), and a method for producing said the protein or polypeptide. The present invention also provides a reactive polyethyleneglycol derivative as an intermediated for above the method. The chemically modified protein or polypeptide of the present invention never impairs bonding with a receptor and has a high plysiological activity. Then, a behaviors in vivo of these substance is improved. Now medical substances or drugs having a high pharmacological activity can be developed by using these substance.
PURPOSE:To produce the title implant material having excellent affinity for organisms and strength by adding a P compd. and a Ca compd. to a soln. of hydrolyzed alkyl silicate to obtain a sol, applying the sol on a titanium alkoxide- coated metal, drying, and calcining the sol. CONSTITUTION:When a metal surface is coated with bioglass, a phosphorus compd. (phosphoric acid, etc.) and a calcium compd. (calcium ethoxide, etc.) are firstly added to a soln. of hydrolyzed alkyl silicate to prepare a sol. A soln. of titanium alkoxide is applied on the surface of a metal (stainless steel, etc.), and then dried. The sol is applied on the obtained coated metal, dried, and then calcined at an appropriate temp. As a result, the metal surface can be firmly coated with the bioglass, hence an implant material having excellent affinity for organisms and strength is obtained, and the material is useful as artificial teeth and bones.
The invention relates to the regulation of the body weight of animals, including mammals and humans, in particular to materials indicated as weight modulators, and to the potentials of applying such modulators in diagnostics and therapy. The invention relates to the discovery and characterization of nucleotide sequences and of proteins about which it is presumed that are expressed by such nucleotides or their variants manifesting their ability to participate in the regulation of mammal body wights. The nucleotide sequences are the genes corresponding to the mouse or human OB gene which is considered to play a key role in the regulation of the body weight and for obesity. According to preliminary data the polypeptide product of the said gene functions are a hormone. The invention also relates to the application of nucleic acid molecules as probes or primers for amplification by polymerase chain reaction (PCR), i.e. synthetic or natural oligonucleotides, to cloning vector containing the nucleic acids, according to this invention, to experession vector in bacteria or in insect or mammal cells and to vector containing the nucleic acids functionally related to a sequence controlling the expression. The invention also relates to a bacterial cell or a mammal cell transfected or transformed by a suitable expression vector, to the application, respectively, to the said structures to antibodies against the OB polypeptides and to a method for the modulation of the body weight of mammals.
Nisin-subtilin mutant and chimeric prepeptides were constructed and expressed in a Bacillus subtilis strain that possesses all of the cellular machinery for making subtilin, except for the presubtilin gene. The chimera SL-Nis1-11-Sub12-32 was prepared. The prepeptide has the subtilin leader sequence (SL), the N-terminal portion of the structural region was derived from nisin, and the C-terminal portion of the structural region derived from subtilin. This chimera was accurately and efficiently converted to the mature lantibiotic, as demonstrated by a variety of physical and biological activity assays. In contrast, a (SL-Sub1-11-Nis12-34) chimera was processed into a heterogeneous mixture of products, none of which appeared to be the correct chimeric lantibiotic. The mixture did, however, contain an active minor component with a biological activity that exceeded nisin itself.
Compositions containing a drug to be delivered and at least one chemical permeation enhancer (CPE), and methods of making and using these compositions are described herein. In a preferred embodiment, the compositions contain two or more CPEs which behave in synergy to increase the permeability of the epithelium, while providing an acceptably low level of cytotoxicity to the cells. The concentration of the one or more CPEs is selected to provide the greatest amount of overall potential (OP). Additionally, the CPEs are selected based on the treatment. CPEs that behave primarily by transcellular transport are preferred for delivering drugs into epithelial cells. CPEs that behave primarily by paracellular transport are preferred for delivering drugs through epithelial cells. Also provided herein are mucoadhesive oral dosage forms. In a preferred embodiment., the oral dosage form is a multi-compartmental device, containing (i) a supporting compartment, (ii) drug compartment and (iii) mucoadhesive compartment.
Both tolerance and physical dependence can develop during chronic opioid therapy. Tolerance is the need for increasing doses of opioids to maintain a defined effect such as analgesia (in the absence of disease progression or other external factors). Tolerance may occur to both the desired and undesired effects of drugs and may develop at different rates for different effects.

Physical dependence is a physiological state in which the body adapts to the drug after a period of regular exposure, resulting in withdrawal symptoms after abrupt discontinuation or a significant dosage reduction of a drug. Withdrawal also may be precipitated through the administration of drugs with opioid antagonist activity (e.g., naloxone, nalmefene), or mixed agonist/antagonist analgesics (e.g., pentazocine, butorphanol, nalbuphine). Physical dependence may not occur to a clinically significant degree until after several days to weeks of continued opioid usage.

Do not abruptly discontinue BELBUCA in a patient physically dependent on opioids. Rapid tapering of BELBUCA in a patient physically dependent on opioids may lead to serious withdrawal symptoms, uncontrolled pain, and suicide. Rapid discontinuation has also been associated with attempts to find other sources of opioid analgesics, which may be confused with drug-seeking for abuse.

When discontinuing BELBUCA, gradually taper the dosage using a patient-specific plan that considers the following: the dose of BELBUCA the patient has been taking, the duration of treatment, and the physical and psychological attributes of the patient. To improve the likelihood of a successful taper and minimize withdrawal symptoms, it is important that the opioid tapering schedule is agreed upon by the patient. In patients taking opioids for a long duration at high doses, ensure that a multimodal approach to pain management, including mental health support (if needed), is in place prior to initiating an opioid analgesic taper [see Dosage and Administration (2.4), Warnings and Precautions (5.14)].

Infants born to mothers physically dependent on opioids will also be physically dependent and may exhibit respiratory difficulties and withdrawal symptoms [see Use in Specific Populations (8.1)].
The internet is a popular method for obtaining information. Increasingly, it is also used to answer medical and health questions, because compared to other methods (e.g. going to the library or visiting a doctor) it has a number of advantages to offer like low costs, availability, easy accessibility, anonymity, and great diversity of information types and sources. 60 to 80 percent of internet users search online for medical information. In this context the term "cyberchondria" was coined in the media to describe the potentially detrimental effects of this behavior. The first studies in this field using self-report retrospective data showed that individuals with elevated levels of health anxiety seem to make increased use of the internet for this purpose and it seems to maintain health anxiety in the long-term. However, up until today little is known about the consequences of this behavior and the maintaining mechanism.

This observational study aims to investigate the effects of health-related internet use in individuals with pathological health anxiety in a naturalistic setting using ambulatory assessment. The variables of interest are monitored using time- and event-based sampling methods. Therefore, over a seven-day period participants answer seven times a day questionnaires on a mobile phone in their usual daily lives and additionally track the variables of interest in the moment the target behavior (health-related internet use) occurs. To our knowledge, this is the first study to investigate these relations using ambulatory assessment and therefore additionally aims to investigate the feasibility of this study design in this specific field of research.
Buprenorphine transdermal system contains buprenorphine, a Schedule III controlled substance. As an opioid, buprenorphine transdermal system exposes users to the risks of addiction, abuse, and misuse [see Drug Abuse and Dependence ( 9)] . Because extended-release products such as buprenorphine transdermal system deliver the opioid over an extended period of time, there is a greater risk for overdose and death, due to the larger amount of buprenorphine present [see Drug Abuse and Dependence (9)]. 

Although the risk of addiction in any individual is unknown, it can occur in patients appropriately prescribed buprenorphine transdermal system. Addiction can occur at recommended doses and if the drug is misused or abused.

Assess each patient’s risk for opioid addiction, abuse, or misuse prior to prescribing buprenorphine transdermal system, and reassess all patients receiving buprenorphine transdermal system for the development of these behaviors and conditions. Risks are increased in patients with a personal or family history of substance abuse (including drug or alcohol abuse or addiction) or mental illness (e.g., major depression). The potential for these risks should not, however, prevent the proper management of pain in any given patient. Patients at increased risk may be prescribed opioids such as buprenorphine transdermal system but use in such patients necessitates intensive counseling about the risks and proper use of buprenorphine transdermal system, along with frequent reevaluation for signs of addiction, abuse, or misuse. Consider prescribing naloxone for the emergency treatment of opioid overdose [see Dosage and Administration (2.2), Warnings and Precautions (5.2), Overdosage (10)]. 

Abuse or misuse of buprenorphine transdermal system by placing it in the mouth, chewing it, swallowing it, or using it in ways other than indicated may cause choking, overdose and death [see Overdosage ( 10)] . 

Opioids are sought for nonmedical use and are subject to diversion from legitimate prescribed use. Consider these risks when prescribing or dispensing buprenorphine transdermal system. Strategies to reduce these risks include prescribing the drug in the smallest appropriate quantity and advising the patient on careful storage of the drug during the course of treatment and the proper disposal of unused drug. Contact local state professional licensing board or state-controlled substances authority for information on how to prevent and detect abuse or diversion of this product.
Delirium and sleep disruption are both common in the intensive care unit (ICU). Delirium is a state of acute confusion, experienced especially by older adults admitted to the hospital, with the potential to adversely impact patients' outcome. Of hospitalized patients, the highest rate of delirium occurs in elderly patients in the ICU. Development of ICU delirium is associated with longer ICU and hospital length of stay, significantly higher risk of functional decline, loss of independent living, and increased mortality. Previous studies have focused on describing the clinical manifestations, risk factors and outcomes of ICU delirium; yet, the contribution of sleep timing, as well as its quality and quantity, to the development of delirium, has not previously been rigorously investigated. Sleep disturbance, including changes in sleep patterns and architecture, and decreased quality of sleep are commonly observed in older subjects. In the ICU, environmental factors (such as noise levels and continuous ambient light) and health care practices (such as frequent performance of medical procedures and tests) further contribute to sleep disruption in the critically ill older patients. Additionally, many sedative and analgesic agents potently suppress slow wave sleep. In preliminary data acquired from ICU patients, the investigators have observed that fragmented sleep is prevalent due to frequent arousals and awakenings, and that sleep architecture is altered with an increase in light sleep, and a decrease in restorative slow wave sleep. Despite the common occurrence of both ICU delirium and sleep disruption, it is not known whether sleep disruption increases the risk of developing delirium in the critically ill older patients. In this exploratory study, the investigators propose to test the hypothesis that the severity and duration of sleep disruption is an independent predictor of the onset and duration of ICU delirium in a cohort of older ICU patients. The investigators will measure sleep disruption using continuous processed electroencephalography and measure ICU delirium using a well-validated and reliable standardized instrument. Results from this study will inform the contribution of sleep disruption in the development of ICU delirium in the older critically ill patients.
Myofascial pain contributes to opioid misuse and opioid use disorder. Alternative non-drug therapies for myofascial pain, such as osteopathic manipulative treatment, are critical areas of research. An unexplored approach in osteopathic manipulative treatment is recruiting the regulatory assistance of the autonomic nervous system (ANS) to alleviate myofascial pain. Autonomic Recalibration Technique (ART) is a manual and behavioral approach that employs osteopathic principles in addressing the neurobiological mechanisms that regulate myofascial pain. Our central hypothesis is that ART utilizes ANS regulation to restore myofascial function and alleviate chronic myofascial pain. The scientific premise of this proposal is the need to document mechanistic evidence that the ANS can be recruited to alleviate and eliminate pain by employing osteopathic principles. While elements of this approach have been employed by various practitioners, including manual and integrative clinicians including osteopaths, the innovation is to combine a manual bottom-up approach to shut down sympathetic tone, and a top-down approach to address trauma-based triggers that propagate pain. If successful, these preclinical data will be used in future grants to propose a clinical trial of ART as an additional technique in osteopathic manipulative treatment to provide an alternative to surgical or drug treatment of chronic myofascial pain.
Data transferred between devices  12/16  is formatted in accordance with a multi-layered data structure. One layer  66  of the multi-layered data structure includes a socket protocol. A layer  68  within the layer  66  includes a header. A payload layer  72  is included within the layer  68 . The header includes information indicative of the type of data in the payload layer  72  and enables multiple data types to be transferred in their original format without conversion. This multi-layered data structure may provide DICOM interactions with medical devices within a hospital secure network  14  to be coupled with external communications mechanisms  16  that can acquire or store NDMA content while maintaining the integrity of the hospital/clinic network security and incorporating strong firewall-like protections. The layer  66  of the multi-layered data structure may further include routing information used to route data received at a destination port  5007  to another port  5005.
Participants receive a 2-hour lesson (at school) promoting active transport for short distance travel to various destinations. Furthermore, they are asked to join a Facebook group on active transport in which 3 messages per week are posted during an eight-week period. The Facebook posts aim to promote the use of active transport for short distance travel.
PLNC8 αβ is a cationic antimicrobial peptide that previously has been reported to express both antibacterial and antiviral properties. This study aimed to further elucidate the antiviral effects of PLNC8 αβ and its impact on virus-induced cytotoxicity and inflammatory signaling in human alveolar epithelial cells (A549) infected with the flavivirus Kunjin. Complementary in silico analyses using molecular dynamics (MD) simulation were conducted to investigate the mechanism of action of PLNC8 αβ by studying the interaction of PLNC8 α and β with models of a flavivirus membrane and a eukaryotic plasma membrane, respectively. Our findings demonstrated that PLNC8 αβ significantly reduces both extracellular and intracellular viral loads, as confirmed by plaque reduction assays and RT-PCR. The peptide also mitigated virus-induced cytotoxicity and inflammation. Notably, PLNC8 αβ modulated the virus-induced dysregulation of key signaling and inflammatory genes, such as TLR9, TLR3, NOD2, FOS, JUN, IL6, and CXCL8. MD simulation revealed that PLNC8 αβ exhibits higher binding affinity for a flavivirus membrane model compared to a model of the plasma membrane, likely due to stronger electrostatic interactions with anionic phospholipids. This selective interaction possibly accounts for a potent antiviral activity of PLNC8 αβ combined with a minimal cytotoxicity toward human cells. Overall, PLNC8 αβ shows significant promise as an antiviral agent against flavivirus infections and warrants further exploration for peptide-based antiviral therapies.
Alcohol intoxication causes serious diseases, whereas current treatments are mostly supportive and unable to remove alcohol efficiently. Upon alcohol consumption, alcohol is sequentially oxidized to acetaldehyde and acetate by the endogenous alcohol dehydrogenase and aldehyde dehydrogenase, respectively. We disclose a hepatocyte-mimicking antidote for alcohol intoxication through the co-delivery of the nanocapsules of alcohol oxidase (AOx), catalase (CAT), and aldehyde dehydrogenase (ALDH) to the liver, where AOx and CAT catalyze the oxidation of alcohol to acetaldehyde, while ALDH catalyzes the oxidation of acetaldehyde to acetate. Administered to alcohol-intoxicated mice, the antidote rapidly accumulates in the liver and enables a significant reduction of the blood alcohol concentration. Moreover, blood acetaldehyde concentration is maintained at an extremely low level, significantly contributing to liver protection. Such an antidote, which can eliminate alcohol and acetaldehyde simultaneously, holds great promise for the treatment of alcohol intoxication and poisoning.